FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Current trends in formulation and application of pharmaceutical preparations in therapy of depression in children and adults

Savremeni trendovi u formulaciji i primeni lekova u terapiji depresije kod dece i odraslih

Thumbnail
2017
2981.pdf (243.6Kb)
Authors
Đuriš, Jelena
Cvijić, Sandra
Aleksić, Ivana
Article (Published version)
Metadata
Show full item record
Abstract
Depression is the most common mental disorder in the general population and often requires long-term administration of antidepressants. Development of the modified release antidepressant products has led to the lower incidence of the adverse effects and improvement in the adherence, and subsequently to better therapeutic outcomes. Modified release may involve delayed and/or prolonged release of antidepressants. There is an increasing number of marketed antidepressant products in the form of orally dispersible tablets, for the treatment of a particular group of patients with impaired swallowing. Pharmacotherapy of depression in children represents a great challenge due to insufficient data regarding efficacy and safety. Furthermore, in the market of Republic of Serbia, there are no antidepressant products in the age-appropriate dosage forms for pediatric patients. It is, therefore, of great importance to address the risks related to the application of the conventional dosage forms of ma...rketed antidepressants (tablets, hard capsules) to children. Novel treatment options include development of carriers for targeted delivery of antidepressants in the central nervous system. Intranasal administration of antidepressants is particularly favored since it allows the delivery of active ingredients via olfactory and trigeminal nerves. Other transmucosal routes of administration, such as buccal or sublingual, can provide improved therapeutic outcomes, compared to the conventional oral administration, due to circumvention of the intense metabolism of the active ingredients and undesired gastrointestinal side effects.

Depresija je najčešći mentalni poremećaj u opštoj populaciji i neretko zahteva dugotrajnu primenu lekova iz grupe antidepresiva. Razvojem preparata sa modifikovanim oslobađanjem lekovite supstance omogućeno je smanjenje neželjenih efekata i poboljšanje adherence, a samim tim i poboljšanje terapijskih ishoda. Modifikacija oslobađanja podrazumeva odloženo i/ili produženo oslobađanje antidepresiva. Za terapiju određene grupe pacijenata sa otežanim gutanjem od velikog značaja je i sve veći broj registrovanih preparata u obliku oralno-disperzibilnih tableta. Farmakoterapija depresije kod dece predstavlja veliki izazov zbog nedostatka podataka o efikasnosti i bezbednosti. Takođe, na tržištu Republike Srbije nisu registrovani preparati sa antidepresivima u farmaceutskim oblicima prilagođenim pedijatrijskom uzrastu. Zbog toga je veoma značajno razmotriti rizike povezane sa primenom konvencionalnih farmaceutskih oblika antidepresiva (tablete, tvrde kapsule) kod dece. Savremeni farmaceutski obli...ci podrazumevaju razvoj nosača za ciljanu isporuku antidepresiva u centralni nervni sistem. Naročito se ističe intranazalni put primene jer omogućava isporuku lekovitih supstanci putem olfaktornog i trigeminalnog nerva. I drugi transmukozni putevi primene, poput bukalnog ili sublingvalnog, omogućavaju unapređenje terapijskih ishoda jer se, u odnosu na peroralni put primene, zaobilazi intenzivan metabolizam lekovitih supstanci i izbegavaju neželjeni gastrointestinalni efekti.

Keywords:
antidepressants / modified release products / novel dosage forms / pharmacotherapy of depression in children / antidepresivi / preparati sa modifikovanim oslobađanjem / savremeni farmaceutski oblici / farmakoterapija depresije kod dece
Source:
Arhiv za farmaciju, 2017, 67, 5, 315-331
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd

DOI: 10.5937/arhfarm1705315D

ISSN: 0004-1963

Scopus: 2-s2.0-85067629612
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/2983
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Đuriš, Jelena
AU  - Cvijić, Sandra
AU  - Aleksić, Ivana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2983
AB  - Depression is the most common mental disorder in the general population and often requires long-term administration of antidepressants. Development of the modified release antidepressant products has led to the lower incidence of the adverse effects and improvement in the adherence, and subsequently to better therapeutic outcomes. Modified release may involve delayed and/or prolonged release of antidepressants. There is an increasing number of marketed antidepressant products in the form of orally dispersible tablets, for the treatment of a particular group of patients with impaired swallowing. Pharmacotherapy of depression in children represents a great challenge due to insufficient data regarding efficacy and safety. Furthermore, in the market of Republic of Serbia, there are no antidepressant products in the age-appropriate dosage forms for pediatric patients. It is, therefore, of great importance to address the risks related to the application of the conventional dosage forms of marketed antidepressants (tablets, hard capsules) to children. Novel treatment options include development of carriers for targeted delivery of antidepressants in the central nervous system. Intranasal administration of antidepressants is particularly favored since it allows the delivery of active ingredients via olfactory and trigeminal nerves. Other transmucosal routes of administration, such as buccal or sublingual, can provide improved therapeutic outcomes, compared to the conventional oral administration, due to circumvention of the intense metabolism of the active ingredients and undesired gastrointestinal side effects.
AB  - Depresija je najčešći mentalni poremećaj u opštoj populaciji i neretko zahteva dugotrajnu primenu lekova iz grupe antidepresiva. Razvojem preparata sa modifikovanim oslobađanjem lekovite supstance omogućeno je smanjenje neželjenih efekata i poboljšanje adherence, a samim tim i poboljšanje terapijskih ishoda. Modifikacija oslobađanja podrazumeva odloženo i/ili produženo oslobađanje antidepresiva. Za terapiju određene grupe pacijenata sa otežanim gutanjem od velikog značaja je i sve veći broj registrovanih preparata u obliku oralno-disperzibilnih tableta. Farmakoterapija depresije kod dece predstavlja veliki izazov zbog nedostatka podataka o efikasnosti i bezbednosti. Takođe, na tržištu Republike Srbije nisu registrovani preparati sa antidepresivima u farmaceutskim oblicima prilagođenim pedijatrijskom uzrastu. Zbog toga je veoma značajno razmotriti rizike povezane sa primenom konvencionalnih farmaceutskih oblika antidepresiva (tablete, tvrde kapsule) kod dece. Savremeni farmaceutski oblici podrazumevaju razvoj nosača za ciljanu isporuku antidepresiva u centralni nervni sistem. Naročito se ističe intranazalni put primene jer omogućava isporuku lekovitih supstanci putem olfaktornog i trigeminalnog nerva. I drugi transmukozni putevi primene, poput bukalnog ili sublingvalnog, omogućavaju unapređenje terapijskih ishoda jer se, u odnosu na peroralni put primene, zaobilazi intenzivan metabolizam lekovitih supstanci i izbegavaju neželjeni gastrointestinalni efekti.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Current trends in formulation and application of pharmaceutical preparations in therapy of depression in children and adults
T1  - Savremeni trendovi u formulaciji i primeni lekova u terapiji depresije kod dece i odraslih
VL  - 67
IS  - 5
SP  - 315
EP  - 331
DO  - 10.5937/arhfarm1705315D
ER  - 
@article{
author = "Đuriš, Jelena and Cvijić, Sandra and Aleksić, Ivana",
year = "2017",
abstract = "Depression is the most common mental disorder in the general population and often requires long-term administration of antidepressants. Development of the modified release antidepressant products has led to the lower incidence of the adverse effects and improvement in the adherence, and subsequently to better therapeutic outcomes. Modified release may involve delayed and/or prolonged release of antidepressants. There is an increasing number of marketed antidepressant products in the form of orally dispersible tablets, for the treatment of a particular group of patients with impaired swallowing. Pharmacotherapy of depression in children represents a great challenge due to insufficient data regarding efficacy and safety. Furthermore, in the market of Republic of Serbia, there are no antidepressant products in the age-appropriate dosage forms for pediatric patients. It is, therefore, of great importance to address the risks related to the application of the conventional dosage forms of marketed antidepressants (tablets, hard capsules) to children. Novel treatment options include development of carriers for targeted delivery of antidepressants in the central nervous system. Intranasal administration of antidepressants is particularly favored since it allows the delivery of active ingredients via olfactory and trigeminal nerves. Other transmucosal routes of administration, such as buccal or sublingual, can provide improved therapeutic outcomes, compared to the conventional oral administration, due to circumvention of the intense metabolism of the active ingredients and undesired gastrointestinal side effects., Depresija je najčešći mentalni poremećaj u opštoj populaciji i neretko zahteva dugotrajnu primenu lekova iz grupe antidepresiva. Razvojem preparata sa modifikovanim oslobađanjem lekovite supstance omogućeno je smanjenje neželjenih efekata i poboljšanje adherence, a samim tim i poboljšanje terapijskih ishoda. Modifikacija oslobađanja podrazumeva odloženo i/ili produženo oslobađanje antidepresiva. Za terapiju određene grupe pacijenata sa otežanim gutanjem od velikog značaja je i sve veći broj registrovanih preparata u obliku oralno-disperzibilnih tableta. Farmakoterapija depresije kod dece predstavlja veliki izazov zbog nedostatka podataka o efikasnosti i bezbednosti. Takođe, na tržištu Republike Srbije nisu registrovani preparati sa antidepresivima u farmaceutskim oblicima prilagođenim pedijatrijskom uzrastu. Zbog toga je veoma značajno razmotriti rizike povezane sa primenom konvencionalnih farmaceutskih oblika antidepresiva (tablete, tvrde kapsule) kod dece. Savremeni farmaceutski oblici podrazumevaju razvoj nosača za ciljanu isporuku antidepresiva u centralni nervni sistem. Naročito se ističe intranazalni put primene jer omogućava isporuku lekovitih supstanci putem olfaktornog i trigeminalnog nerva. I drugi transmukozni putevi primene, poput bukalnog ili sublingvalnog, omogućavaju unapređenje terapijskih ishoda jer se, u odnosu na peroralni put primene, zaobilazi intenzivan metabolizam lekovitih supstanci i izbegavaju neželjeni gastrointestinalni efekti.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Current trends in formulation and application of pharmaceutical preparations in therapy of depression in children and adults, Savremeni trendovi u formulaciji i primeni lekova u terapiji depresije kod dece i odraslih",
volume = "67",
number = "5",
pages = "315-331",
doi = "10.5937/arhfarm1705315D"
}
Đuriš, J., Cvijić, S.,& Aleksić, I.. (2017). Current trends in formulation and application of pharmaceutical preparations in therapy of depression in children and adults. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 67(5), 315-331.
https://doi.org/10.5937/arhfarm1705315D
Đuriš J, Cvijić S, Aleksić I. Current trends in formulation and application of pharmaceutical preparations in therapy of depression in children and adults. in Arhiv za farmaciju. 2017;67(5):315-331.
doi:10.5937/arhfarm1705315D .
Đuriš, Jelena, Cvijić, Sandra, Aleksić, Ivana, "Current trends in formulation and application of pharmaceutical preparations in therapy of depression in children and adults" in Arhiv za farmaciju, 67, no. 5 (2017):315-331,
https://doi.org/10.5937/arhfarm1705315D . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB